Is FDA up or down today?
FDA is up 0.65% today, last at 38.21. This stock moved +0.65% versus the prior close.
FDA · FDA
FDA (FDA) is trading at 38.21, up 0.65% on the session. Price signals are mixed — no clear one-way momentum read.
Over the past 7 days, 32 headlines skew mixed. Earnings and Management themes dominated coverage.
Social buzz is mixed — no strong crowd signal.
Analyst firms are mostly reiterating — no strong directional shift lately.
FDA is up 0.65% today, last at 38.21. This stock moved +0.65% versus the prior close.
Over the past 7 days, 32 headlines skew mixed. Earnings and Management themes dominated coverage. Dominant story: Johnson & Johnson Just Got FDA Clearance for Its Surgical Robot, Hiked Its Dividend for the 64th Time, and Is Targeting $100 Billion in Revenue. But Here's What Investors Should Be Most Excited About (1 source, neutral) RSI unavailable Price sits at 50% of its 52-week range Live social: 50% of recent mentions lean bullish — mixed social mood.
Historical price chart unavailable
Live quote in the header is real, but OHLC history could not be loaded from Yahoo Finance or fallback providers. Charts use Yahoo when configured correctly — check server logs for provider errors.
Analyst firms are mostly reiterating — no strong directional shift lately.
Query: FDA
18/ 100 index
-28% vs start of window
Based on 2 mentions over 30d
Not enough social mentions yet
Johnson & Johnson Just Got FDA Clearance for Its Surgical Robot, Hiked Its Dividend for the 64th Time, and Is Targeting $100 Billion in Revenue. But Here's What Investors Should Be Most Excited About
FDA IDE pivotal trial and 2027 cash runway for enVVeno Medical (NASDAQ: NVNO) - Stock Titan
Aardvark shares plunge 32% after FDA halts clin... - Pluang
Capricor Therapeutics (CAPR) Shares Plunge 45% After FDA Advisory Panel Vote - GuruFocus
Aardvark Therapeutics (AARD) Scrutinized Again After FDA Hold on Lead Drug Candidate, May Announcement Drives Stock 32% Lower - Hagens Berman - PR Newswire
FDA approves Retatrutide this year?
Will Trump announce Kyle Diamantas as the next FDA commissioner by December 31?